Skip to the note

Term / Self-pay

Self-pay: the medicine price and the rest of the bill.

Self-pay means paying outside insurance. Put the medicine price and the care fee on separate lines.

Ask for a bill you can compare

  • What does a normal month cost after any starting offer?
  • Is medicine included, or billed on its own?
  • Are tests and check-in visits extra?
  • How does renewal work, and how do I cancel?
Morning light across a quiet courtyard, with a wide window and a lavender-grey wall.

A dated cash-price example

Read the form and the offer terms

On September 26, 2026, the drug maker listed self-pay Zepbound (tirzepatide) at $299–$699 for a 28-day supply, depending on strength.

That range applied to vials, small medicine bottles, and the KwikPen, a pen holding several injections.

A separate $449 offer for higher strengths required a refill within 45 days of the previous delivery.

Those recorded terms run through December 31, 2026, so a later refill needs a fresh price check.

Keep this medicine-only example apart from the program’s total fee.

Ask the insurance plan about the exact product

A plan’s drug list is called its formulary.

When the plan agrees ahead of time to pay, that agreement is called prior authorization.

Give the plan the exact product name, its form and the condition being treated. Ask what approval is needed and what you would pay.

Medicare: ask which way it could pay

The usual medicine plan and the temporary program differ

As of September 26, 2026, Medicare’s usual medicine benefit, called Part D, excludes treatment used only for weight loss.

Part D can pay for Mounjaro for type 2 diabetes, meaning high blood sugar, or Zepbound for moderate to severe sleep apnea, a breathing problem during sleep, in adults with obesity.

Obesity means a high level of excess body weight. The plan’s list of medicines and its agreement in advance still determine payment.

GLP-1 is one of the gut hormones, chemical messages that affect appetite and blood sugar; tirzepatide acts like this hormone.

The temporary program named Medicare GLP-1 Bridge runs outside the usual Part D payment system; people who meet its rules pay $50 for a monthly supply.

For tirzepatide, it includes the Zepbound KwikPen, but excludes vials and pens used for just one injection.

The recorded program starts on July 1, 2026, and ends on December 31, 2027.

Have your prescription writer check how Medicare could pay, using your exact medicine name and diagnosis.

Who can use the temporary program?

The age rule is 18 or older, so age 80 alone does not exclude you. You need both a prescription and advance approval.

You must also have a Medicare medicine plan that meets these rules. It may be a Part D plan on its own, or Medicare Advantage with coordinated care and medicine cover.

The weight and health checks use your situation when treatment began; BMI is the weight measure used in these rules.

Ask your prescriber, the person writing your prescription, to compare your BMI and diagnosis records with these three choices:

  • BMI of 35 or higher.
  • BMI of 30 or higher, plus a listed heart, blood-pressure or kidney problem.
  • BMI of 27 or higher, along with pre-diabetes (blood sugar raised before diabetes), a heart attack or stroke in the past, or symptoms caused by poor blood flow in the limbs.

For the middle choice, only one type of heart failure is on the list. Its diagnosis name is “heart failure with preserved ejection fraction.”

Bring the name from your medical records so the prescriber can check whether it matches.

For the blood-pressure choice, the upper reading must stay above 140 or the lower one above 90 mm Hg, even with two blood-pressure medicines. Blood pressure is measured in mm Hg.

The kidney choice means disease at stage 3a or higher, a level recorded in your diagnosis.

Type 2 diabetes or moderate to severe sleep apnea rules out the Bridge because those uses go through the usual Part D plan instead.

One particular fatty liver condition also rules it out. The diagnosis must be the type named MASH, with moderate to advanced liver scarring and without the separate diagnosis called cirrhosis.

A diagnosis of fatty liver by itself does not settle this rule; the prescriber needs to check the full diagnosis.

Having a GLP-1 medicine paid for by Part D in 2026 bars you from the Bridge during 2026. The recorded rules have not yet set this check for 2027.

The prescription must be part of ongoing changes in food and physical activity, with organised support for those changes.

Next term: Boxed warning